No Data
EyePoint Pharmaceuticals | 10-Q: Quarterly report
TD Cowen Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Cuts Target Price to $20
EyePoint Pharmaceuticals: Advancements in Clinical Trials and Promising Interim Data Boost Buy Rating
EyePoint Pharmaceuticals: Q3 Earnings Snapshot
Express News | EyePoint Pharmaceuticals Inc: $161.0 Mln Oversubscribed Equity Financing Extends Cash Runway Into 2027
Earnings Flash (EYPT) EYEPOINT PHARMACEUTICALS Posts Q3 Revenue $10.5M